All News
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.
Read Article
Rheum Manpower Needs - More Programs! (12.2.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/CVDbXtqOBw https://t.co/R4ed2FNxdh
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/Qyp2odOfpj https://t.co/Q1qdv0CQ5P
Links:
Dr. John Cush RheumNow ( View Tweet)
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
https://t.co/6pqRZO2VNA https://t.co/iJfhyRs8nw
Links:
Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe!
Rheum Manpower Needs - More Programs
https://t.co/W0mOCkyJbI https://t.co/USXTAtrE6U
Links:
Dr. John Cush RheumNow ( View Tweet)
The spicy topic of turmeric in RA
Curcumin has increasingly been promoted as a potential RA therapy, but data presented at #ACR22 suggests it is unable to do any better than placebo in replacing conventional rheumatoid arthritis therapies.
https://t.co/C0O0DyXn34 https://t.co/kv3dw476dT
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual target blockade may be better than one in SLE
Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE).
https://t.co/uu6ygb4l8B https://t.co/nLO3oSiEVa
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in rheumatic diseases
Dr. Antoni Chan ( @synovialjoints) discusses abstracts 0510 and 0404 at #ACR22
https://t.co/7SSJITLrRT https://t.co/utjf8vlJof
Links:
Dr. John Cush RheumNow ( View Tweet)
AI Future of Sacroiliitis Assessment
Dr. Rachel Tate ( @uptoTate) speaks with Dr. Fabian Proft about Abstract 0383 at #ACR22 Convergence.
https://t.co/pfeW4iQBLq https://t.co/0lFx6CpWCx
Links:
Dr. John Cush RheumNow ( View Tweet)
Can I stop Methotrexate in RA?
Dr. Pope and Dr. Meng discuss Abstract 0916 at #ACR22.
https://t.co/0hK5kNHlrS https://t.co/AXJija7Yzo
Links:
Dr. John Cush RheumNow ( View Tweet)
Remibrutinib in Sjogren's Syndrome
Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
https://t.co/ymFkNWPaXo https://t.co/0k6vLIu0Ku
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheum Drugs & IDSA Guidelines to Treat COVID-19
https://t.co/39wTAKW83E https://t.co/ir1x66FSQ8
Links:
Dr. John Cush RheumNow ( View Tweet)
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with ILD associated with CTD are treated with either intravenous RTX or CTX, but with fewer adverse events with RTX.
https://t.co/5yaPDaw8pZ https://t.co/kcKLkIv1bK
Links:
Dr. John Cush RheumNow ( View Tweet)
Recent CDC/MMWR report shows Paxlovid x 5days (including those w/ prior COVID or vaccination), had a 51% lower hospitalization rate within 30 days after diagnosis than those not prescribed Paxlovid. Use it irrespective of vaccination status https://t.co/CBc1VBSDFR https://t.co/EC8QGaFrb3
Links:
Dr. John Cush RheumNow ( View Tweet)
Future therapy? Nanoparticles laced with rapamycin to nanoparticle stimulate regulatory T cells to suppress autoimmune disease (tested in a mouse model). https://t.co/JHFh82siff https://t.co/Y8itPXiPho
Links:
Dr. John Cush RheumNow ( View Tweet)
Impressive free read and review of Neutrophils and Netosis in Autoimmune and Autoinflammatory disorders (Nature Reviews) from Kapland & Wigerblad at the NIH. https://t.co/w4cIwcQMkt https://t.co/ReA9xM2X4j
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts - Lupus Part2
#ACR22 Daily Recap: Saturday Recap New Treatments for SLE?
https://t.co/uRI3Q3eI6E https://t.co/wBXfXw7z8J
Links:
Dr. John Cush RheumNow ( View Tweet)
Just Can’t Get Enough of Hydroxychloroquine
Several studies on HCQ dosing were presented in the poster and abstract sessions. HCQ has numerous benefits backed by evidence and unless absolutely contraindicated, patients should be maintained on it. Yet...
https://t.co/n8drUDDDjh https://t.co/AIoV3s2VhJ
Links:
Dr. John Cush RheumNow ( View Tweet)